Comparison · NCT00091507-e64b8529
GIK -- vs Placebo: Progression of Acute Coronary Syndrome to Myocardial Infarction
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. GIK -- vs Placebo: Progression of Acute Coronary Syndrome to Myocardial Infarction. Trial comparisons, record NCT00091507-e64b8529. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00091507-e64b8529
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.487 | 0.439 | 0.535 | wilson | |
| Risk in group 2 | 0.526 | 0.48 | 0.571 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0395 | -0.105 | 0.0269 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.925 | 0.811 | 1.06 | log | |
| Odds ratio, group 1 over group 2 | 0.854 | 0.654 | 1.11 | log | |
| Number needed to treat, for one fewer participant with the outcome on GIK -- than on Placebo | 25.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | GIK -- | GIK = glucose-insulin-potassium | 200 | 411 | OG000 |
| Group 2 | Placebo | Dextrose 5% | 242 | 460 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Progression of Acute Coronary Syndrome to Myocardial Infarction
- Description
- Outcome for all participants during the first 24 hours of hospitalization; evidence of myocardial infarction is determined by ECG and biomarker results.
- Time frame
- 24 hours
- Population
Source ClinicalTrials.gov
Trial
- Title
- IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.
- NCT number
- NCT00091507
- Phases
- PHASE3
- Conditions
- Angina, Unstable, Cardiovascular Diseases, Heart Diseases, Coronary Disease, Myocardial Infarction, Heart Failure, Congestive
- Interventions
- GIK, Placebo
- Lead sponsor
- Tufts Medical Center
- Results first posted
- 2013-01-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00091507?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00091507-e64b8529